Advertisement

Investigational New Drugs

, Volume 1, Issue 3, pp 253–258 | Cite as

Characterization of the pharmacokinetics of bisantrene (NSC-337766)

  • John G. Kuhn
  • Thomas M. Ludden
  • J. William Myers
  • Daniel D. Von Hoff
Clinical

Summary

The pharmacokinetics of bisantrene, 9,10-anthracenedicarboxaldehyde bis ((4,5-dihydro-1 H-imidazol-2-yl) hydrazone) dihydrochloride were evaluated during a Phase I clinical investigation. Bisantrene at doses of 20 to 280 mg/m2 was administered by variable infusion rates to nine patients with advanced metastatic cancer. Bisantrene's plasma clearance followed a triexponential pattern with a harmonic mean terminal half-life (t1/2 γ) of 26 h. The steady state volume of distribution (Vd ss ) was large, averaging 627 l/m2. Plasma clearance averaged 42.6±6.7 l/h/m2. The cumulative urinary excretion of bisantrene was 3.6±1.6% at 48 h.

Key words

bisantrene CL216,942 pharmacokinetics in humans 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Von Hoff DD, Coltman CA Jr, Forseth B: Activity of 9–10 anthracenedicarboxaldehyde bis ((4,5-dihydro-1H-imidazol-2-yl)hydrazone) dihydrochloride (CL 216,942) in a human tumor cloning system: Leads for a phase II trial in man. Cancer Chemother Pharmacol 6:141–144, 1981Google Scholar
  2. 2.
    Citarella RV, Wallace RE, Murdock KC, Angier RB, Durr FE: Antitumor activity of CL216,942: 9,10-anthracenedicar-boxaldehyde bis ((4,5 dihydro-1H-imidazol-2-yl)hydrazone) dihydrochloride. Abstracts of the 20th Interscience Conference of Antimicrobial Agents and Chemotherapy. September, 1980, Abstract #23Google Scholar
  3. 3.
    Wu WH, Nicolau G: Disposition and metabolic profile of a new antitumor agent: CL216,942 (bisantrene) in laboratory animals. Cancer Treat Rep 66:1173–1185, 1982Google Scholar
  4. 4.
    Von Hoff DD, Myers JW, Kuhn JG, Sandbach JF, Pocelinko R, Clark G, Coltman CA Jr: Phase I clinical investigation of 9,10-anthracenedicarboxaldehyde bis ((4,5-dihydro-1 H-imidazol-2-yl)hydrazone) dihydrochloride (CL216,942). Cancer Res 41:3118–3121, 1981Google Scholar
  5. 5.
    Boxenbaum HG, Riegeiman S, Elashoff RM: Statistical estimations in pharmacokinetics. J Pharmacokinet Biopharm 2:123–48, 1974Google Scholar
  6. 6.
    Powis G: Reversed-phase high-performance liquid Chromatographie assay for the antineoplastic agent 9,10-anthracene-dicarboxaldehyde bis ((4,5-dihydro-1 H-imidazol-2-yl)hydrazone) dihydrochloride. J Chromatogr 226:514–520, 1981Google Scholar
  7. 7.
    Powis G, Kovach JS: Disposition of bisantrene in humans and rabbits: Evidence for intravascular deposition of drug as a cause of phlebitis. Cancer Res 43:925–928, 1983Google Scholar

Copyright information

© Martinus Nijhoff Publishers 1983

Authors and Affiliations

  • John G. Kuhn
    • 1
    • 2
    • 3
  • Thomas M. Ludden
    • 2
    • 3
  • J. William Myers
    • 4
  • Daniel D. Von Hoff
    • 1
  1. 1.Department of Medicine, Division of OncologyUniversity of Texas Health Science Center at San Antonio and Audie Murphy VA HospitalSan AntonioUSA
  2. 2.Department of PharmacologyUniversity of Texas Health Science Center at San AntonioSan AntonioUSA
  3. 3.College of Pharmacy, University of Texas at AustinAustinUSA
  4. 4.Medical Oncology Service, Department of MedicineWilford Hall USAF Medical CenterSan AntonioUSA

Personalised recommendations